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Abstract 
Deep Brain Stimulation (DBS) has been introduced as an innovative treatment for several 
neurological disorders, including Parkinson’s disease, essential tremor, and dystonia and it has 
been proven effective in helping individuals affected by these disorders; hence, enhancing 
their quality of life. DBS has also been investigated for the treatment of cluster and other 
primary headaches.  Electrodes are surgically implanted into brain structures, for example the 
posterior hypothalamus in case of cluster headache. Hypothalamic DBS has been successfully 
used to treat patients with cluster headache and short-lasting unilateral neuralgiform 
headache with conjunctival injection and tearing (SUNCT). In these headache conditions, DBS 
may reduce headache frequency by half, however, some side effects have also been reported 
that are mainly related to infection where the electrodes are placed, syncope, and diplopia. 
Hypothalamic DBS is proposed to modulate neuronal structures that are directly or indirectly 
involved in detection or transmission of painful stimuli or in the processing of this information. 
Reports of the use of DBS for chronic migraine are not found in the literature. This 
commentary explores the medical hypothesis that DBS could be considered as a therapeutic 
option for intractable chronic migraine. This hypothesis is based on the commonalities 
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between cluster headache and migraine in terms of some shared symptoms, and potential 
overlap of underlying mechanisms. However, due to the absence of clinical evidence 
supporting the use of DBS in CM, the fact that disease-specific optimization of DBS parameters 
must be considered carefully, and considering the optimal CNS structures to target are 
currently unknown, it is concluded that this interventional and invasive technique should be 
avoided for CM for the present time. 
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1. Medical Hypothesis 
Chronic migraine (CM) is a debilitating neurological disorder. Here, we put forward the 
hypothesis that deep brain stimulation (DBS) is a potential late option to treat severe intractable 
cases of CM and that the benefit is greater than the risks for those affected patients. This hypothesis 
has been formed based on 1) the observation that increased hypothalamic activity is associated with 
both cluster headache (CH) [1] and migraine [2] attacks; and 2) the demonstration that electrical 
stimulation of the hypothalamus (hypothalamic DBS) is effective for treating CH [3-5]. These 
observations support the idea that DBS might be beneficial for CM; however, the nature of this 
technique is invasive and side effects [6] may occur. Therefore, to test this hypothesis, appropriate 
CM patient selection must be taken into consideration. It is proposed that DBS be limited to use in 
the most complicated cases, where no other option is available, such as resistance to all other forms 
of CM therapy [4, 7]. 
2. Chronic Migraine 
The International Headache Society classification of headache disorders (ICHD-3) defines CM as 
“headache occurring on ≥15 days/month for more than 3 months with features of migraine on 
≥8 days/month” [8]. Up to 5% of the general population are affected by CM [9]. CM is less common 
than episodic migraine (EM); however, headache-related disability is higher and consequently the 
quality of life of affected individuals is lower [10-12]. Annually, about 3% of patients with EM 
progress to CM [13]. Similar symptoms of migraine may accompany CM that include nausea, 
vomiting, photophobia, and phonophobia, but these are often less pronounced compared with EM 
[14]. Co-morbid conditions such as psychiatric and other somatic medical conditions are also higher 
in CM [15], leaving the affected individuals with a complex, difficult-to-treat condition. The burden 
of CM [16] is considerable and poses both individual and societal consequences [17, 18]. 
It is not yet clear how or for what reason EM progresses into CM in some individuals [19]; 
however, some potentially modifiable risk factors have been identified, which include the frequency 
of headache attacks, medication overuse, insufficient acute treatment, stress, and obesity [13, 20]. 
Identification of risk factors and application of appropriate treatments for acute migraine attacks 
can reduce headache frequency, severity, and disability; however, patients with CM are generally 
considered candidates for prophylactic therapy [21, 22]. Pharmacological options are limited, but 
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high-quality evidence (level A) exists for the preventive therapy of CM with FDA approved agents 
such as propranolol, divalproex sodium, botulinum neurotoxin A, and topiramate [23, 24]. 
Nevertheless, a systematic review, including both observational studies and data from randomized 
clinical trials [25] has highlighted that poor patient adherence exists for migraine prophylaxis 
regimens that can be due to low tolerability or frequent dosing intervals. In addition, many 
prophylactic agents are only partially effective; providing 50% relief in approximately 50% of 
patients [26], while the side effects and cost of prolonged treatment often limit patient compliance. 
A recent meta-analysis [27] indicates that the newly introduced CGRP monoclonal antibodies 
(eptinezumab, erenumab, galcanezumab, and fremanezumab) are effective in CM, but long-term 
safety is still under investigation [28]. Alternative techniques such as behavioral and cognitive 
therapy [29], exercise, and stress management [23] have also been used with variable beneficial 
outcomes [30]. Those patients with CM who use available pharmacological treatments and still have 
inadequate pain relief or disabling side effects may turn to other therapeutic modalities, such as 
neuromodulation. 
3. Neuromodulation in Migraine 
A number of neuromodulatory strategies has been introduced for prevention of CM [31], which 
include non-invasive peripheral neurostimulation techniques such as occipital nerve stimulation, 
transcutaneous supraorbital stimulation, transcranial direct current stimulation, and repetitive 
magnetic stimulation [32]. These techniques need to be investigated further and are often among 
the later therapeutic choices for complex cases of CM resistant to other types of treatments [33]. It 
is beyond the scope of this manuscript to give a complete systematic review of all neurostimulation 
techniques investigated for migraine. We refer the readers to excellent reviews already available [7, 
34-38].  
The basis for neuromodulation in CM stems from evidence that demonstrates that migraine is a 
disorder of neuroplasticity and that migraine chronification results from a maladaptive process, 
which leads to the development of a hyper-excitability state in the brain. Several hypotheses exist 
to explain the pathogenesis of CM, such as functional brain changes in affected patients, including 
increased cortical excitability, central trigemino-thalamic sensitization, and dysfunctional 
descending pain modulation [39-41]. These alterations have been linked to comorbid conditions, 
including analgesic overuse, chronic stress, anxiety, or depression that can further influence pain-
processing pathways in migraine [40]. Sensitization of trigeminal and thalamic neurons has been 
postulated to be a potential key mechanism in the progression from EM to CM [40, 42].  The reversal 
of such plastic changes in the brain has led researchers to become interested in applying brain 
stimulation as a potential therapeutic option for migraine [32]. These techniques induce changes of 
neural plasticity that persist beyond the period of stimulation, which is fundamental to the 
prophylactic treatment of migraine, as they may target the neurophysiological abnormalities that 
contribute to the transition from EM to CM [32]. CEFALY©  is a commercially available device that 
stimulates the supraorbital branch of the trigeminal nerve with electrodes placed on the forehead. 
For the prevention of EM, a 20 min stimulation once a day with the CEFALY device was 
demonstrated to decrease headache days per month compared with the sham stimulation group (p 
= 0.054) [43]. In 2019, Chou et al. [44] showed that treatment with CEFALY©  could abort pain during 
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acute migraine attacks. However, the efficacy of this device for prophylaxis of CM is not yet 
supported by sufficient evidence. The technique is safe and easy to use [45, 46].  
Vagus nerve stimulation (VNS) with an implanted vagus nerve stimulator was originally used for 
epileptic patients with migraine comorbidity, where it was found that it could improve migraine in 
these patients and therefore was considered as an option for migraine [47]. GammaCore©  is a 
medical device developed to provide non-invasive VNS. This device is applied to the skin over the 
cervical branch of the vagus nerve and its use in animal models has been found to reduce cortical 
spreading depression [48]. In 2014, Oshinsky et al. [49] presented data on VNS that indicated it could 
reduce allodynia and that this effect was correlated with levels of extracellular glutamate in the 
subnucleus caudalis (Vc) of the spinal trigeminal nucleus. Non-invasive VNS has been demonstrated 
to reduce pain during migraine attacks within 20 min of headache onset [50]. However, in the EVENT 
study by Silberstein et al. [51], use of non-invasive VNS in CM patients was not beneficial. This 
technique is also safe, but substantial evidence for its beneficial effects in CM is lacking.  
Remote electrical neuromodulation (REN) has also been used to abort acute pain during migraine 
attacks [52, 53]. In this technique, peripheral nerves of the upper arm are stimulated through a 
wireless wearable battery-operated stimulation unit controlled by a smartphone software 
application. The device is worn on the lateral upper arm to stimulate small cutaneous C and Aδ 
fibers for 45 min [54]. According to the manufacturer, the stimulation energy is low enough to 
maintain the overall sensory experience below perceptual pain threshold, at so called “sub-
nociceptive” intensity. In contrast to transcutaneous electrical nerve stimulation (TENS) that is 
sensed as touch because it excites primarily Aβ fibers, and produces pain relief through inhibition 
of ascending pain (gate control theory), Nerivio™ induces pain relief by activation of brain stem-
mediated descending pain inhibition. This phenomenon is known as conditioned pain modulation 
(CPM), where a second painful stimulus can reduce the original pain [55]. Producers of Nerivio™ 
have also reported that stimulation by this device triggers global release of serotonin and 
norepinephrine, hence reinforcing endogenous analgesic mechanisms. Current data [54] show that 
Nerivio™ has a favorable safety profile for the acute treatment of migraine. 
Transcranial direct current stimulation (tDCS) is another technique that works by modulating 
cerebral cortical excitability and has been postulated to reduce migraine, since cortical spreading 
depression (CSD) [56] is a possible trigger of migraine [57]. A systematic review of 8 studies on tDCS 
in the prevention of migraine has provided evidence for a positive effect [58]. However, due to the 
small sample size and large degree of heterogeneity in the studies included in this systematic review, 
the quality of evidence is low and needs further confirmatory studies.  
The other available techniques are transcranial magnetic stimulation (TMS) and repetitive TMS 
(rTMS) that are also proposed to modulate CSD [57, 59]. Experimental data in rats and cats have 
shown that single pulse TMS could block experimentally induced CSD [60]. Andreou et al. [60] 
elegantly presented data that CSD can be blocked in vivo by single pulse TMS and highlighted its 
thalamocortical modulatory capacity. This study was the first to show that the most important 
region of action was on thalamic neurons and that the trigeminocervical complex appeared less 
involved [60]. A systematic review by Stilling et al. in 2019 [58], which included both rTMS and TMS 
studies, presented data for an overall beneficial outcome in terms of reduction in headache 
frequency, duration, intensity, and analgesic use for acute migraine pain. SpringTMS© , a portable 
and rechargeable medical device was tested in a trial in 2010 [61], where it was demonstrated that 
39% of patients became pain-free at 2 h after application of the device on the occipital region and 
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the administration of two stimulations [61]. Two studies from 2015 [62] and 2018 [63] also reported 
efficacy and tolerability of the device in migraineurs with or without aura. Adverse effects related 
to the application of this device have been dizziness, tinnitus, and worsening of migraine, but with 
mild to moderate intensity and transient features [62, 63]. 
In addition to the above mentioned non-invasive techniques, there are invasive techniques to 
treat primary headaches [38]. Transient stimulation of the spheno-palatine ganglion (SPG), chronic 
occipital nerve stimulation (ONS), and stimulation of retro-hypothalamic area by DBS are currently 
listed as invasive stimulation techniques [38]. Spheno‑palatine ganglion stimulation (SPGS) has been 
proposed to work through several mechanisms, one of which is targeting the parasympathetic 
nervous system involved in the pathophysiology of trigeminal autonomic cephalalgias [64]. 
Pulsante® is a medical device, developed for SPGS to abort CH attacks in patients with chronic CH 
(CCH). SPGS might also be indicated in patients with CM, but evidence is lacking in this population 
[38]. 
Although a number of studies [34, 65] have provided evidence for somewhat beneficial effects 
of ONS, for example a significant reduction in headache days and disability [66], the exact underlying 
mechanism is still debated. It is proposed that ONS probably works by modulation of the trigemino-
cervical complex [67]. However, a delayed response in many patients has opened up the possibility 
of a more complex mechanism that involves non-specific regulation of central pain control systems. 
Functional neuroimaging techniques have provided evidence of metabolic changes following ONS 
in the regions suggested as pain processing regions, in particular in the anterior cingulate cortex 
[68].  
DBS is the therapeutic use of chronic electrical stimulation of the brain via an implanted electrode 
[69]. It is most commonly used to treat the motor symptoms of Parkinson’s disease (PD), and has 
occasionally been used or investigated for the treatment of a wide variety of other neurological and 
psychiatric conditions [70] including epilepsy, obsessive-compulsive disorder (OCD), major 
depression, and CCH. DBS in the posterior hypothalamus is the most commonly used and most 
promising method for reduction of pain in refractory CCH. Other brain targets that include 
stimulation at the junction between the diencephalic and mesencephalic tegmentum [71-73] have 
also been suggested and tried for CCH. Readers are referred to papers on the effectiveness of DBS 
to treat attacks of CH assessed by Leone’s group [3-5, 74, 75] and others [73, 76]. 
DBS is considered a last choice option for prevention of CH in patients with CCH who fulfill the 
selection criteria, namely at least 2 years of disease duration, at least one attack per day, resistance 
to pharmacotherapy, headache limited to the same side, normal neurological examination, and 
absence of psychiatric comorbidity [4, 7]. 
4. DBS for CCH 
DBS was originally proposed for CCH to target the attack generator, which was hypothesized to 
be located in the posterior hypothalamic region [74, 75]. This hypothesis was supported by 
functional neuroimaging techniques that demonstrated that this region is activated during CH 
attacks [1, 77]. Long-term hypothalamic stimulation was first reported in 2001 in a patient with CCH 
[78], where pain relief was observed with no major side effects. This technique was then further 
used for 16 drug-resistance CCH patients [79]. Long-term follow up after 4 years showed that 10 
patients remained in a pain-free state [79].  
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According to Pedersen et al. [80], in addition to an inhibitory effect of DBS on the CH generator, 
located in the hypothalamus or the adjacent mesencephalic gray, two other potential mechanisms 
might explain the DBS effect in CH. One theory describes activation of the periaqueductal gray (PAG) 
and/or rostral ventromedial medulla (RVM), that are both parts of the pain modulatory system, as 
the mechanism by which DBS decreases pain. The second theory describes a potential long-term 
effect on the pain-processing pathways [81, 82]. The exact targeted structures that lead to a 
beneficial effect of DBS for CCH are still debated. However, collectively, it has been proposed that 
effective DBS for CCH modulates a more widespread network of the brain, rather than a single 
region, and the network potentially  includes the trigeminal nuclei, PAG, hypothalamus, thalamus 
and cortical areas [83]. Advancement in neuroimaging studies, including PET and resting-state fMRI, 
shed further light into the contribution of the hypothalamus/midbrain tegmentum in CH, and 
consequently different targets for DBS were considered such as inferior-posterior hypothalamus, 
midbrain tegmentum, and ventral tegmental area (for review see [84]). Further investigation also 
found changes in functional connectivity of not only these regions, but also relevant connections to 
pain-related areas, supporting the hypothesis that a complex matrix might be involved in 
modulating CH attacks [84]. 
Recently, Nowacki and his team have published a meta-analysis [85] to present estimates and 
predictors of long‐term pain relief based on the cohorts of patients undergoing DBS for CCH. This 
group found that in 40 patients in four different cohorts, mean reduction in headache frequency 
was 77% during a follow‐up of 44 months, with an overall response rate of 75%. A map of brain 
region stimulation for therapeutic effect of DBS identified the midbrain ventral and retrorubral 
tegmentum as important sites [85]. This meta-analysis also reinforces the current view that DBS in 
the ventral tegmental area probably acts upon pain circuits involved in maintaining CH [36]. Due to 
the finding that the therapeutic effect takes several weeks to manifest, it has been hypothesized 
that DBS in the ventral tegmentum induces a functional modulation of the pain processing network 
rather than pure inhibition of hypothalamic activity [77, 86].  
Interestingly, trigeminal perception and pain thresholds have been measured following posterior 
hypothalamic DBS and reports showed that pain perception is only moderately decreased in 
peripheral limbs [87]. However, electrical pain thresholds or nociceptive reflexes within the 
trigeminal innervation territory remained unchanged [87]. Another study [88] has demonstrated 
that, in patients with drug-resistant CCH undergoing posterior hypothalamic DBS, cold pain 
thresholds in the receptive field of the ophthalmic branch of the trigeminal nerve were increased 
on the DBS stimulated side. The DBS group also had higher cold detection thresholds compared to 
non-implanted cluster headache patients. The authors of this study concluded that 
neurostimulation of the posterior hypothalamus is specific for CH and only certain aspects of pain 
sensation can be affected [88]. Collectively, these observations also point to a more complex 
mechanism of action underlying hypothalamic DBS for CCH, rather than a direct, simple analgesic 
effect. 
Only a proportion of patients respond to the DBS procedure. The reason is not completely 
understood. It was originally proposed that placement of electrode might be a potential reason. 
However, findings from a PET study [86] demonstrated that failure of DBS for CCH is not directly 
related to electrode placement, which suggests that other factors might be involved. No clinical or 
physiological marker can be used to assess the correct positioning of the electrodes. In addition, it 
seems that identification of exact stimulated areas is challenging. In an MRI study [89], which 
OBM Neurobiology 2021; 5(1), doi:10.21926/obm.neurobiol.2101082 
 
Page 7/20 
investigated the effect of stimulating electrode locations in patients with drug-resistant CCH, no 
difference was found in anatomical location of stimulating electrodes between responders and non-
responders.  
Nevertheless, DBS is not a risk-free procedure, is not considered a routine treatment for CH, and 
is only used in centers with extensive experience. Although the number of cases with critical safety 
issues, such as hemorrhage, is limited, risk of bleeding is around 3% [34]. Several cases of panic 
attack with dysautonomia, oculomotor disturbances, intraoperative transient ischemic attack, 
subcutaneous infection, transient loss of consciousness with hemiparesis and micturition syncope, 
erectile dysfunction, headache and tremor, euphoria, and paroxysmal sneezing have been reported 
in the literature [34]. On the other hand, sleep quality has been shown improved following posterior 
hypothalamic DBS in CH by the suppression of nocturnal attacks [90]. 
5. DBS for CM 
According to the results of our literature search, clinical use of DBS for CM has not been reported. 
This might be due to the fact that several noninvasive and somewhat effective neuromodulatory 
techniques are available for migraine [31]. However, none of the currently available 
pharmacological or non-pharmacological strategies produces 100% efficacy and hence one can 
hypothesize that other options could be effective for those who are not responsive to the currently 
available treatments. One such option may be DBS. Since DBS has shown promise for treatment of 
patients with debilitating refractory CCH who are not responsive to other available treatments, it is 
hypothesized that patients with intractable CM might benefit from DBS. This medical hypothesis is 
based on evidence that shows that migraine and CH [91] share common features, which include 
certain clinical signs and symptoms, overlap with activated brain regions, and response to both 
pharmacological and neuromodulatory treatments. These observations point to a common link 
between these two types of primary headaches that most likely stems from underlying 
pathophysiological mechanisms, for example hyperexcitability of the brain network, progressive 
changes in nociceptive thresholds, and subsequent central sensitization [92]. Successful targeting 
of both conditions with triptans, some neurostimulation techniques, and novel data on CGRP 
monoclonal antibodies also suggest that both conditions may share some overlapping pathways [93, 
94]. For a comprehensive review of the links between migraine and CH, please see [95]. Figure 1 
depicts some of the common features between CH and CM. 




Figure 1 Examples of common features between cluster headache and migraine. Several 
characteristics share commonalities between these two primary headaches from clinical 
aspects to brain images, and response to some treatment strategies. For a 
comprehensive review, please see [92]. 
One interesting observation is the hyperperfusion, as a surrogate parameter for increased brain 
activity in the hypothalamus, that occurs both in CH and in migraine attacks [95]. Maniyar et al. [96] 
have found that activity in the hypothalamus is increased in the early premonitory phase of migraine, 
supporting a migraine mediator role for hypothalamus in addition to activation in the brain stem, 
the dorsal rostral pons, and the PAG [42, 96, 97]. Leone’s group firstly hypothesized that high-
frequency hypothalamic stimulation would inhibit apparent hyperactivity of this brain area and his 
theory was tested successfully in 2001 [78]. Progress on a putative mechanism of action of 
hypothalamic stimulation benefitted from PET studies in CH patients treated with hypothalamic DBS. 
In these patients, hypothalamic stimulation provoked increased blood flow in both the ipsilateral 
posterior inferior hypothalamic grey at the site of the electrode tip, and the ipsilateral trigeminal 
system [86], where for the first time a functional connection between the hypothalamus and the 
trigeminal system in humans was documented in vivo. Interestingly, activation of the trigeminal 
system did not provoke any headache attack, trigeminal pain, or features of autonomic craniofacial 
stimulations, and these findings led to the hypothesis that the activation of trigeminal system might 
contribute to CH attack but on its own cannot explain the attacks [86]. This observation, together 
with required latency of chronic stimulation to see the clinical effects of DBS propose a complex 
mechanism that might include the modulation of the antinociceptive system, i.e., increased 
threshold for cold pain [88]. Additionally, hypothalamic stimulation has resulted in elevated blood 
flow in brain areas known as pain matrix, such as the thalamus, somatosensory cortex, precuneus, 
and anterior cingulate cortex, but decreased blood flow in the middle temporal gyrus, posterior 
cingulate cortex, and insula [86]. Collectively, the evidence shows that hypothalamic stimulation 
interferes with components of this matrix and its therapeutic role might be by a gradual restoration 
of the normal function and metabolism in hypometabolic brain areas in patients with CCH [98]. This 
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interpretation [99] is based on the accumulated experience that has changed the view of the 
hypothalamus as a generator of the CH attack to a modulator of the CH attack [100].  
CH is also associated with dysautonomias, which are a group of conditions in which changes in 
the activity or function of the autonomic nervous system (ANS) negatively affect health [101]. Thus, 
the effects of DBS on the function of ANS has also attracted increased interest [102]. In a study by 
Cortelli et al, in 2007 [6], in patients with CH who were receiving posterior hypothalamic stimulation 
to identify the effects on headache, the orthostatic sympathoexcitatory response showed an 
increase during the head uptilt testing (HUTT) [6]. When DBS was off, a 3% fall was observed in 
systolic blood pressure during the HUTT. However, when DBS stimulation was on, systolic blood 
pressure was maintained when the HUTT was repeated. An increase was observed in both diastolic 
blood pressure and total peripheral resistance for HUTT during the on versus the off mode of DBS 
stimulation [6]. These findings suggested that DBS could affect the peripheral vascular system. Heart 
rate variability (HRV), an index of autonomic activity, is widely used in clinical studies.  Vagal 
parasympathetic effects cause high-frequency changes in heart rate. Hypothalamic stimulation in 
patients with CH increases the ratio of low-frequency to high-frequency HRV components. This 
finding suggests that hypothalamic DBS could activate the sympathetic nervous system. In contrast, 
during the CH attack in untreated patients, a reverse HRV pattern was observed, where a significant 
reduction in low-frequency HRV values was found, that is interpreted as autonomic nervous system 
dysfunction [103]. Other cardiovascular abnormalities have also been reported in patients during 
the CH attacks, including increases or decreases in heart rate and rhythm, atrial fibrillation, and 
heart block [103, 104]. Collectively, these data provide evidence that autonomic function is also 
altered by hypothalamic DBS. For a review, see [102]. 
As the exact mechanism underlying DBS efficacy in CCH remains uncertain [35, 37], a discussion 
of how DBS might work for CM remains purely speculative.  
Theoretically, one can consider other mechanisms that might underlie hypothalamic DBS for CM. 
DBS has been found to increase extracephalic pain thresholds in some CH patients [35, 37]. This 
suggests that deep brain stimulation may be reducing output from the posterior hypothalamus. In 
rats, it has been shown that there are direct connections between the paraventricular nucleus (PVN) 
of the hypothalamus and the trigeminal Vc, where trigeminovascular neurons that relay painful 
input from the dura are located [105]. Inhibition of the PVN decreases the response of these Vc 
neurons to meningeal stimulation, which suggests that this input from the PVN to the Vc is 
excitatory and thus pronociceptive. One possibility is that DBS, by activating local inhibitory 
interneurons in the PVN, decreases output from the PVN to the Vc. However, this possibility is 
inconsistent with the PET study in CH discussed above, which indicated increased neuronal activity 
not only in the PVN but also in the Vc after long term DBS for CH [86]. One way to account for this 
finding in human CH patients is to propose that the use of DBS over time results in neuroplastic 
changes in the Vc. These changes would involve the formation of synaptic connections from the 
PVN to local inhibitory interneurons within the Vc. As a result, DBS of the PVN would, over time, 
increase the inhibitory tone in the Vc, and thus increase the activation threshold of 
trigeminovascular neurons. Figure 2 illustrates these two potential mechanisms.  
Similar to CH, dysautonomias also accompany migraine attacks [106]; however, it is too early to 
comment on any potential effects of DBS on dysautonomias in migraine.  




Figure 2 A theoretical model to present how DBS of the posterior hypothalamus could 
act to decrease CM. Red indicates excitation, blue inhibition. Nociceptive input from the 
dura and face activates second order trigeminovascular neurons, which transmit this 
information to the sensory cortex by way of the thalamus. The hypothalamus makes 
excitatory connections with the Vc that increase trigeminovascular neuron excitability. 
(1) DBS of the posterior hypothalamus over time decreases hypothalamic output, 
decreasing trigeminal sensory neuron excitability. (2) DBS of the posterior hypothalamus 
over time results in new connections to inhibitory interneurons in the Vc, decreasing 
trigeminal sensory neuron excitability. Theoretically, either mechanism would lead to 
higher thresholds for headache pain, and/or decreased intensity of this pain. 
6. Safety and Patient Selection for DBS 
Transient visual disturbances, diplopia, vertigo, nausea, euphoria, bradycardia, and appetite 
changes have been reported as the main side effects following DBS of the posterior hypothalamus. 
Serious events have also been documented such as intracerebral hemorrhage, hardware infection, 
transient loss of consciousness, and skin erosion or hardware malfunction [107]. Lead fracture is 
another common complication. In a follow up study (1996–2007) [108], the long-term incidence of 
lead fractures in patients who underwent DBS surgery was determined. This retrospective study 
[108] was conducted on 208 patients who received 387 DBS electrodes, where 18 lead fractures 
were identified in 16 patients. Radiological screening has been suggested to determine the location 
and incidence of lead fracture in patients [108]. 
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Considering the invasive nature of DBS, and associated risks, one must consider that use of DBS 
for CM, if it were to become an option, must be limited to a patient who is intolerant or has failed 
to achieve benefit from medications or non-invasive neuromodulation techniques. Currently, due 
to lack of sufficient evidence, it is not possible to determine the risk versus benefit for DBS in the 
treatment of CM. Hence, future potential use of DBS for CM should be considered based on each 
individual patient’s case in relation to safety, and tolerability. Similar to the process of initiation of 
DBS for CH, which started from individual cases, or case series, the use of DBS for CM would be 
considered on a case by case basis, and neurologists would be encouraged to report their findings 
if they have employed this technique for one or more CM patients. Lessons learned from small trials 
in CH [109] can be a useful starting point for CM. Fontaine et al [109] performed the first prospective 
crossover, double-blind, multicenter study assessing the efficacy and safety of unilateral 
hypothalamic DBS in 11 patients with severe refractory CCH. Active and sham stimulation were 
compared during 1-month periods within the randomized part of the trial. Then, the study was 
followed by an open label phase for one year [109]. Researchers assessed headache severity and 
frequency, pain intensity, sumatriptan injection use, emotional impact, and quality of life. The 
randomized phase of this study did not support the efficacy of DBS in refractory CCH, but findings 
from the open phase suggested long-term efficacy in more than 50% patients. Three serious adverse 
events were recorded, which included subcutaneous infection, transient loss of consciousness, and 
micturition syncope [109]. Comments raised about this trial by Ambrosini and  Schoenen [110] 
highlight several points to be considered.  Their concerns may also be applicable for a potential 
feasibility study for use of DBS in CM. Based on the findings from the randomized part of the study,  
Ambrosini and  Schoenen [110] raised a valid point about the duration of treatment, which was that 
one month might be a rather short period for a therapeutic effect due to the potential for DBS to 
induce slow neuromodulatory changes.  The delayed response in the open phase of the study shows 
that responders needed a longer duration of stimulation to benefit from DBS [110].  
Patient selection with the aid of biomarkers, such as neuroimaging biomarkers [111], for example 
evidence of activation of hypothalamus [112], potential bio-based biomarkers, such as plasma levels 
of CGRP or certain miRNAs [113, 114], or predictive biomarkers for migraine chronification, such as 
polymorphism of certain genes [115], would allow for proper patient selection and stratification of 
patients (EM, and CM) prior to the DBS trials in CM.  
It is important to note that CM is often complicated by other conditions, for example medication 
overuse headache [116], or can coexist with other disorders, such as epilepsy [117]. Therefore, it is 
also rational to consider, pre-DBS, if other treatments should be considered, for example a period 
of the detoxification therapy in the case of medication overuse headache [118]. In addition, for 
conditions comorbid with CM, it is logical to consider if potential use of DBS for those conditions 
may improve CM. For example, a case study [119] has shown that following anterior thalamic DBS 
for drug-resistant idiopathic generalized seizure, improvement has also been noticed in CM.  
Collectively, the literature supports the notion of careful patient selection for DBS, i.e., restricted 
to patients who are resistant to all available treatments, including non-invasive preventive 
treatments.  It also supports a longer time course of DBS treatment, in addition to a rational 
selection of primary and secondary end-points for determination of efficacy. Based on sufficient 
evidence, statements and guidelines could be developed similar to what is already available for DBS 
to treat CCH [7]. Such guidelines could also be drafted in the future, evaluated, and approved for 
CM. For an optimal DBS in CM, one must also consider that DBS for CM must be adjusted to be 
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disease-specific. Therefore, the pattern of DBS application (i.e. parameters of frequencies and 
intensities) and format (i.e., continuous or intermittent) should be first optimized for CM. In addition, 
it is useful to report if any observation presents that co-existing conditions with CM undergoing DBS 
could indirectly affect migraine, because this would allow collecting relevant data and potential 
target structure for stimulation. Both positive and negative data must be reported. For example, an 
indirect beneficial effect in CM has been reported following anterior thalamic DBS for a case of co-
existing epilepsy [119], however, subthalamic DBS in a case of Parkinson’s disease [120], did not 
exert any  significant change for CM co-existed with the Parkinson’s disease (see the abstract P196 
in [120]). 
7. Conclusion 
This commentary presents a medical hypothesis that the use of DBS might open a new 
therapeutic avenue for CM patients. Based on evidence that DBS has been effective in CH patients, 
and the fact that the pathogenesis of CH and CM shares some common features, we presented 
some pros and cons of considering DBS for CM. On one hand, this invasive technique could be 
justified in cases of CM who are not responders to any available treatments. A balance between 
benefit and harm needs to be carefully considered, based on the safety and long-term outcomes of 
DBS for CH, prior to patient selection and, for that reason, DBS for CM would be expected to initially 
involve individual patient cases.  Ethical considerations and safety issues must also be justified case-
by case to minimize the risks to patients. A clear communication between patients and clinicians 
would help to identify potential benefits and risks, patient preference, clinician’s recommendation, 
and available options prior to a final decision. Case reports from these individual patient trials might 
then be used to justify if further evaluation of DBS might be an option for randomized controlled or 
open label studies. The individual patient trial data would also suggest the length of treatment 
needed before significant improvement in CM symptoms might be expected. In addition, due to the 
fact DBS might be used for those conditions that co-exist with CM, observations of improvement in 
CM, while treating such co-existing conditions must be reported. This would allow collection of 
relevant data and potentially the structural targets for beneficial DBS for CM. This approach has 
already appeared in the literature, where DBS for epilepsy [119] and Parkinson’s disease [120], was 
reported to exert beneficial or no effects on CM, respectively. Similarly, it was also reported that 
subthalamic DBS not only produced beneficial effects in advanced Parkinson’s disease but could also 
alleviate CH [121].  
In short, DBS could be of potential benefit for CM, either directly or indirectly, where CM co-
exists with other conditions that are being treated with DBS. The potential use of DBS for chronic, 
debilitating CM resistant to other non-invasive alternatives remains open, but at this stage, we await 
accumulation of sufficient clinical evidence before any general statement can be formulated for 
application of DBS in CM.  In line with this view, disease-specific optimization of DBS parameters 
that include the most relevant CNS structures to be targeted with DBS for CM must be considered.  
Such parameters for CM remain to be determined. 
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